AIMS: Recent-onset dilated cardiomyopathy (RODCM) is characterized by heterogeneous aetiology and diverse clinical outcomes, with scarce data on genotype-phenotype correlates. Our aim was to correlate individual RODCM genotypes with left ventricular reverse remodelling (LVRR) and clinical outcomes. METHODS AND RESULTS: In this prospective study, a total of 386 Czech RODCM patients with symptom duration ≤6 months underwent genetic counselling and whole-exome sequencing (WES). The presence of pathogenic (class 5) or likely pathogenic (class 4) variants in a set of 72 cardiomyopathy-related genes was correlated with the occurrence of all-cause death, heart transplantation, or implantation of a ventricular assist device (primary outcome) and/or ventricular arrhythmia event (secondary outcome). LVRR was defined as an improvement of left ventricular ejection fraction to >50% or ≥10% absolute increase, with a left ventricular end-diastolic diameter ≤33 mm/m2 or ≥10% relative decrease. Median follow-up was 41 months. RODCM was familial in 98 (25%) individuals. Class 4-5 variants of interest (VOIs) were identified in 125 (32%) cases, with 69 (18%) having a single titin-truncating variant (TTNtv) and 56 (14%) having non-titin (non-TTN) VOIs. The presence of class 4-5 non-TTN VOIs, but not of TTNtv, heralded a lower probability of 12-month LVRR and proved to be an independent baseline predictor both of the primary and the secondary outcome. The negative result of genetic testing was a strong protective baseline variable against occurrence of life-threatening ventricular arrhythmias. Detection of class 4-5 VOIs in genes coding nuclear envelope proteins was another independent predictor of both study outcomes at baseline and also of life-threatening ventricular arrhythmias after 12 months. Class 4-5 VOIs of genes coding cytoskeleton were associated with an increased risk of life-threatening ventricular arrhythmias after baseline assessment. A positive family history of dilated cardiomyopathy alone only related to a lower probability of LVRR at 12 months and at the final follow-up. CONCLUSIONS: RODCM patients harbouring class 4-5 non-TTN VOIs are at higher risk of progressive heart failure and life-threatening ventricular arrhythmias. Genotyping may improve their early risk stratification at baseline assessment.

1st Internal Clinic of Cardio Angiology St Anne's University Hospital and Medical School of Masaryk University Brno Czech Republic

Department of Cardiology Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Cardiovascular Medicine 2nd Department of Medicine 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Department of Internal Medicine 1 Cardiology University Hospital Olomouc Olomouc Czech Republic

Department of Pathological Physiology Faculty of Medicine and Dentistry Palacky University Olomouc Olomouc Czech Republic

Department of Pediatrics and Adolescent Medicine 1st Faculty of Medicine Research Unit for Rare Diseases Charles University Prague Czech Republic

European Reference Network for Rare Low Prevalence and Complex Diseases of the Heart ERN GUARD Heart IKEM Prague Czech Republic

Institute of Physiology 1st Faculty of Medicine Charles University Prague Czech Republic

Zobrazit více v PubMed

Bozkurt B, Colvin M, Cook J, Cooper LT, Deswal A, Fonarow GC, et al. Current diagnostic and treatment strategies for specific dilated cardiomyopathies. Circulation 2016;134:e579‐e646. doi:10.1161/CIR.0000000000000455 PubMed DOI

Merlo M, Pyxaras SA, Pinamonti B, Barbati G, di Lenarda A, Sinagra G. Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment. J Am Coll Cardiol 2011;57:1468‐1476. doi:10.1016/j.jacc.2010.11.030 PubMed DOI

Givertz MM, Mann DL. Epidemiology and natural history of recovery of left ventricular function in recent onset dilated cardiomyopathies. Curr Heart Fail Rep 2013;10:321‐330. doi:10.1007/s11897-013-0157-5 PubMed DOI PMC

Kubanek M, Sramko M, Maluskova J, Kautznerova D, Weichet J, Lupinek P, et al. Novel predictors of left ventricular reverse remodeling in individuals with recent‐onset dilated cardiomyopathy. J Am Coll Cardiol 2013;61:54‐63. doi:10.1016/j.jacc.2012.07.072 PubMed DOI

Spezzacatene A, Sinagra G, Merlo M, Barbati G, Graw SL, Brun F, et al. Arrhythmogenic phenotype in dilated cardiomyopathy: Natural history and predictors of life‐threatening arrhythmias. J Am Heart Assoc 2015;4:e002149. doi:10.1161/JAHA.115.002149 PubMed DOI PMC

Kayvanpour E, Sedaghat‐Hamedani F, Amr A, Lai A, Haas J, Holzer DB, et al. Genotype‐phenotype associations in dilated cardiomyopathy: Meta‐analysis on more than 8000 individuals. Clin Res Cardiol 2017;106:127‐139. doi:10.1007/s00392-016-1033-6 PubMed DOI

Peters S, Kumar S, Elliott P, Kalman JM, Fatkin D. Arrhythmic genotypes in familial dilated cardiomyopathy: Implications for genetic testing and clinical management. Heart Lung Circ 2019;28:31‐38. doi:10.1016/j.hlc.2018.09.010 PubMed DOI

Taylor MR, Fain PR, Sinagra G, Robinson ML, Robertson AD, Carniel E, et al. Familial dilated cardiomyopathy registry research group. Natural history of dilated cardiomyopathy due to lamin A/C gene mutations. J Am Coll Cardiol 2003;41:771‐780. doi:10.1016/s0735-1097(02)02954-6 PubMed DOI

Kumar S, Baldinger SH, Gandjbakhch E, Maury P, Sellal JM, Androulakis AF, et al. Long‐term arrhythmic and nonarrhythmic outcomes of laminA/C mutation carriers. J Am Coll Cardiol 2016;68:2299‐2307. doi:10.1016/j.jacc.2016.08.058 PubMed DOI

van Rijsingen IA, van der Zwaag PA, Groeneweg JA, Nannenberg EA, Jongbloed JD, Zwinderman AH, et al. Outcome in phospholamban R14del carriers: Results of a large multicentre cohort study. Circ Cardiovasc Genet 2014;7:455‐465. doi:10.1161/CIRCGENETICS.113.000374 PubMed DOI

Ortiz‐Genga MF, Cuenca S, Dal Ferro M, Zorio E, Salgado‐Aranda R, Climent V, et al. Truncating FLNC mutations are associated with high‐risk dilated and arrhythmogenic cardiomyopathies. J Am Coll Cardiol 2016;68:2440‐2451. doi:10.1016/j.jacc.2016.09.927 PubMed DOI

Begay RL, Graw SL, Sinagra G, Asimaki A, Rowland TJ, Slavov DB, et al. Filamin C truncation mutations are associated with arrhythmogenic dilated cardiomyopathy and changes in the cell‐cell adhesion structures. JACC Clin Electrophysiol 2018;4:504‐514. doi:10.1016/j.jacep.2017.12.003 PubMed DOI PMC

Parikh VN, Caleshu C, Reuter C, Lazzeroni LC, Ingles J, Garcia J, et al. Regional variation in RBM20 causes a highly penetrant arrhythmogenic cardiomyopathy. Circ Heart Fail 2019;12:e005371. doi:10.1161/CIRCHEARTFAILURE.118.005371 PubMed DOI PMC

Domínguez F, Cuenca S, Bilińska Z, Toro R, Villard E, Barriales‐Villa R, et al. European Genetic Cardiomyopathies Initiative Investigators. Dilated cardiomyopathy due to BLC2‐associated Athanogene 3 (BAG3) mutations. J Am Coll Cardiol 2018;72:2471‐2481. doi:10.1016/j.jacc.2018.08.2181 PubMed DOI PMC

Hershberger RE, Hedges DJ, Morales A. Dilated cardiomyopathy: The complexity of a diverse genetic architecture. Nat Rev Cardiol 2013;10:531‐547. doi:10.1038/nrcardio.2013.105 PubMed DOI

Haas J, Frese KS, Peil B, Kloos W, Keller A, Nietsch R, et al. Atlas of the clinical genetics of human dilated cardiomyopathy. Eur Heart J 2015;36:1123‐1135. doi:10.1093/eurheartj/ehu301 PubMed DOI

McNally EM, Mestroni L. Dilated cardiomyopathy: Genetic determinants and mechanisms. Circ Res 2017;121:731‐748. doi:10.1161/CIRCRESAHA.116.309396 PubMed DOI PMC

Herman DS, Lam L, Taylor MR, Wang L, Teekakirikul P, Christodoulou D, et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med 2012;366:619‐628. doi:10.1056/NEJMoa1110186 PubMed DOI PMC

van Spaendonck‐Zwarts KY, van Rijsingen IA, van den Berg MP, Lekanne Deprez RH, Post JG, van Mil AM, et al. Genetic analysis in 418 index patients with idiopathic dilated cardiomyopathy: Overview of 10 years' experience. Eur J Heart Fail 2013;15:628‐636. doi:10.1093/eurjhf/hft013 PubMed DOI

Jansweijer JA, Nieuwhof K, Russo F, Hoorntje ET, Jongbloed JD, Lekanne Deprez RH, et al. Truncating titin mutations are associated with a mild and treatable form of dilated cardiomyopathy. Eur J Heart Fail 2017;19:512‐521. doi:10.1002/ejhf.673 PubMed DOI

Tobita T, Nomura S, Fujita T, Morita H, Asano Y, Onoue K, et al. Genetic basis of cardiomyopathy and the genotypes involved in prognosis and left ventricular reverse remodeling. Sci Rep 2018;8:1998. doi:10.1038/s41598-018-20114-9 PubMed DOI PMC

Gigli M, Merlo M, Graw SL, Barbati G, Rowland TJ, Slavov DB, et al. Genetic risk of arrhythmic phenotypes in patients with dilated cardiomyopathy. J Am Coll Cardiol 2019;74:1480‐1490. doi:10.1016/j.jacc.2019.06.072 PubMed DOI PMC

Verdonschot JAJ, Hazebroek MR, Wang P, Sanders‐van Wijk S, Merken JJ, Adriaansen YA, et al. Clinical phenotype and genotype associations with improvement in left ventricular function in dilated cardiomyopathy. Circ Heart Fail 2018;11:e005220. doi:10.1161/CIRCHEARTFAILURE.118.005220 PubMed DOI

Escobar‐Lopez L, Ochoa JP, Mirelis JG, Espinosa MÁ, Navarro M, Gallego‐Delgado M, et al. Association of genetic variants with outcomes in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol 2021;78:1682‐1699. doi:10.1016/j.jacc.2021.08.039 PubMed DOI

Silverdal J, Sjöland H, Pivodic A, Dahlström U, Fu M, Bollano E. Prognostic differences in long‐standing vs. recent‐onset dilated cardiomyopathy. ESC Heart Fail 2022;9:1294‐1303. doi:10.1002/ehf2.13816 PubMed DOI PMC

Pinto YM, Elliott PM, Arbustini E, Adler Y, Anastasakis A, Böhm M, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non‐dilated cardiomyopathy, and its implications for clinical practice: A position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2016;37:1850‐1858. doi:10.1093/eurheartj/ehv727 PubMed DOI

Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: Executive summary. Circulation 2013;128:1810‐1852. doi:10.1161/CIR.0b013e31829e8807 PubMed DOI

Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification. J Am Soc Echocardiogr 2005;18:1440‐1463. doi:10.1016/j.echo.2005.10.005 PubMed DOI

Quinones MA, Otto CM, Stoddard W, Waggoner A, Zoghbi WA. Recommendations for quantification of Doppler echocardiography. J Am Soc Echocardiogr 2002;15:167‐184. doi:10.1067/mje.2002.120202 PubMed DOI

Kalia SS, Adelman K, Bale SJ, Chung WK, Eng C, Evans JP, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): A policy statement of the American College of Medical Genetics and Genomics. Genet Med 2017;19:249‐255. doi:10.1038/gim.2016.190 PubMed DOI

Richards S, Aziz N, Bale S, Bick D, das S, Gastier‐Foster J, et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405‐424. doi:10.1038/gim.2015.30 PubMed DOI PMC

Jordan E, Peterson L, Ai T, Asatryan B, Bronicki L, Brown E, et al. Evidence‐based assessment of genes in dilated cardiomyopathy. Circulation 2021;144:7‐19. doi:10.1161/CIRCULATIONAHA.120.053033 PubMed DOI PMC

Owens AT, Day SM. Reappraising genes for dilated cardiomyopathy: Stepping Back to move forward. Circulation 2021;144:20‐22. doi:10.1161/CIRCULATIONAHA.121.054961 PubMed DOI

https://gnomad.broadinstitute.org/. Accessed January 2015 to June 2020.

Hershberger RE, Givertz MM, Ho CY, Judge DP, Kantor PF, McBride KL, et al. Genetic evaluation of cardiomyopathy – A Heart Failure Society of America Practice Guideline. J Card Fail 2018;24:281‐302. doi:10.1016/j.cardfail.2018.03.004 PubMed DOI PMC

Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno‐Blanes J, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis. Eur Heart J 2013;34:2636‐2648. doi:10.1093/eurheartj/eht210 PubMed DOI

Corden B, Jarman J, Whiffin N, Tayal U, Buchan R, Sehmi J, et al. Association of titin‐truncating genetic variants with life‐threatening cardiac arrhythmias in patients with dilated cardiomyopathy and implanted defibrillators. JAMA Netw Open 2019;2:e196520. doi:10.1001/jamanetworkopen.2019.6520 PubMed DOI PMC

Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med 2016;375:1221‐1230. doi:10.1056/NEJMoa1608029 PubMed DOI

Zeppenfeld K, Tfelt‐Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, et al. ESC Scientific Document Group. 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 2022;43:3997‐4126. doi:10.1093/eurheartj/ehac262 PubMed DOI

Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales‐Villa R, Basso C, et al. 2023 ESC guidelines for the management of cardiomyopathies. Eur Heart J 2023;44:3503‐3626. doi:10.1093/eurheartj/ehad194 PubMed DOI